Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome)

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Amphotericin b may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Amphotericin b

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Amphotericin B Gilead liposomal is an antifungal antibiotic. The active ingredient in Amphotericin B Gilead liposomal is amphotericin B. Amphotericin B Gilead liposomal is given as an infusion into a vein (a drip) in hospital by a doctor or nurse. Amphotericin B Gilead liposomal is used to treat serious infections caused by fungi: ▪

Fungal infections of one or more deep organs of the body.

▪

Suspected fungal infections in patients with a raised temperature and neutropenia. Neutropenia is a reduced number of white blood cells called neutrophils. These are important in fighting infections. Neutropenia can be a side effect of cancer treatments. Before you are given Amphotericin B Gilead liposomal your doctor will check that your fever is not due to bacteria or viruses. You will probably have had one or more antibiotics already. A fever which continues despite treatment may be due to a fungal infection. It's difficult to confirm this with current tests, however.

▪

Visceral leishmaniasis, a disease caused by a parasite.

What you need to know before you take it

Amphotericin B Gilead liposomal

Severe allergic reaction (anaphylactic or anaphylactoid) can occur at any point of treatment of Amphotericin B Gilead liposomal. Therefore each dose of Amphotericin B Gilead liposomal should be given slowly by infusion into the vein over a 30 – 60 minute period and you will be closely observed every time.

Your doctor will not give you Amphotericin B Gilead liposomal

  • If you are allergic (hypersensitive) to Amphotericin B or any of the other ingredients of Amphotericin B Gilead liposomal. However, if your condition is life-threatening you may be given Amphotericin B Gilead liposomal if your doctor believes that only Amphotericin B Gilead liposomal can help you.
  • If you have previously experienced a severe allergic reaction (anaphylactic or anaphylactoid) to Amphotericin B Gilead liposomal. Symptoms of such immediate and life-threatening allergic reactions include: flushing, itching, sickness, swelling of the face, mouth, tongue and airways, often enough to cause difficulty breathing. Warnings and precautions Your doctor will take special care with Amphotericin B Gilead liposomal
  • If you have a severe allergic (anaphylactic) reaction. If this happens your doctor will stop the infusion.
  • If you get other reactions related to the infusion. If this happens, your doctor may slow down the infusion, so you receive Amphotericin B Gilead liposomal over a longer period of time (approximately 2 hours). Your doctor may also give you medicines to prevent or treat infusion-related reactions, such as diphenhydramine (an antihistamine), paracetamol, pethidine (for pain relief) and/or hydrocortisone (an anti-inflammatory medicine that works by reducing the response of your immune system).
  • If you are taking other medicines that may cause kidney damage, see section Other medicines and Amphotericin B Gilead liposomal. Amphotericin B Gilead liposomal may cause damage to the kidney. Your doctor or nurse will take blood samples. This is to test creatinine (a chemical in the blood that reflects kidney function), and electrolyte levels (particularly potassium and magnesium) before and during the treatment with Amphotericin B Gilead liposomal because both of these can be abnormal if you have kidney problems. This is particularly important if you have previous renal damage or if you are taking other medicines that may cause damage to the kidney. The blood samples will also be tested for changes in your liver, and your body's ability to produce new blood cells and platelets.
  • If blood tests show a change in kidney function, or other important changes. If this happens, your doctor may give you a lower dose of Amphotericin B Gilead liposomal or stop treatment.
  • If blood tests show that your potassium levels are low. If this happens, your doctor may prescribe a potassium supplement for you to take while you are treated with Amphotericin B Gilead liposomal.
  • If blood test shows that your potassium levels are high you may suffer irregular heartbeat, sometimes severe.
  • If you have a white blood cell transfusion. Sudden and severe problems in the lungs can happen if you are given Amphotericin B Gilead liposomal infusion during or shortly after a white blood cell transfusion. Your doctor will recommend that the infusions are separated by as long a period as possible. This will reduce the risk of lung problems, and your lungs will be monitored.
  • If you have had kidney failure and are having dialysis. Your doctor may start Amphotericin B Gilead liposomal treatment after the procedure has ended.
  • If you have diabetes. Amphotericin B Gilead liposomal contains approximately 900 mg of sucrose (sugar) in each vial. Tell your doctor if you have diabetes. Other medicines and Amphotericin B Gilead liposomal Tell your doctor if you are taking any other medicines, or have recently taken any. This includes medicines and herbal products you bought without a prescription.

Medicines that may cause kidney damage: ▪

Medicines that suppress the immune system (immunosuppressants), such as ciclosporin and tacrolimus.

  • Certain antibiotics called aminoglycosides (including gentamicin, neomycin and streptomycin) and polymixins.
  • Pentamidine a medicine used to treat pneumonia in people with AIDS and leishmaniasis.  Tell your doctor if you are taking any of these medicines. Amphotericin B Gilead liposomal may make any kidney damage caused by the medicine worse. If you are taking any of these medicines, your doctor or nurse will take regular blood samples to check your kidneys. Medicines that may lower your potassium levels: • ▪ ▪ ▪ ▪

Corticosteroids, anti-inflammation medicines that work by reducing the response of your immune system. Corticotropin (ACTH), used to control the amount of corticosteroid produced by your body. The body produces corticosteroid in response to stress. Diuretics, medicines that increase the amount of urine your body produces. This includes furosemide. Digitalis glycosides, medicines produced from the foxglove plant and used to treat heart failure. Amphotericin B Gilead liposomal may worsen the side effects of digitalis, such as heart rhythm changes. Muscle relaxants usually used during surgery, such as tubocurarine. Amphotericin B Gilead liposomal may increase the muscle relaxant effect.

Other medicines: ▪ ▪ ▪

Antifungal medicines, such as flucytosine. Amphotericin B Gilead liposomal may worsen the side effects of flucytosine. This includes changes in the body's ability to produce new blood cells. This may be seen in blood tests. Certain cancer medicines, such as methotrexate, doxorubicin, carmustine and cyclophosphamide. Taking this type of medicine with Amphotericin B Gilead liposomal may cause kidney damage, wheezing or trouble breathing and low blood pressure. White blood cell (leukocyte) transfusions. Sudden and severe problems in the lungs can happen if you are given Amphotericin B Gilead liposomal infusion during or shortly after a white blood cell transfusion. Your doctor will recommend that the infusions are separated by as long a period as possible. This will reduce the risk of lung problems and your lungs will be monitored.

Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will only prescribe Amphotericin B Gilead liposomal if they think the benefits of treatment outweigh the risks to you and your unborn child or your baby. Driving and using machines Do not drive or operate machinery Some of the possible side effects of Amphotericin B Gilead liposomal could affect your ability to drive or use machines safely, See Section 4, Possible side effects. Amphotericin B Gilead liposomal contains sugar

Tell your doctor if you have diabetes. Amphotericin B Gilead liposomal contains approximately 900 mg of sugar (sucrose) in each vial. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially 'sodium-free'.

How to take it

Amphotericin B Gilead liposomal Amphotericin B Gilead liposomal is always given to you by a doctor or nurse. It is given into a vein (a drip). Amphotericin B Gilead liposomal must not be given by any other method. To prepare the infusion Amphotericin B Gilead liposomal must be dissolved in sterile water for injection and then diluted with a solution containing dextrose. Amphotericin B Gilead liposomal must not be mixed with saline (salt) solutions or with other medicinal products or electrolytes. Amphotericin B Gilead liposomal is not interchangeable with other amphotericin products. Each dose of Amphotericin B Gilead liposomal should be given slowly by infusion into the vein over a 30 – 60 minute period and you will be closely observed every time. If a severe

allergic reaction occurs, the infusion will be immediately discontinued, and you will not receive further infusion of Amphotericin B Gilead liposomal. Use in adults Your dose of Amphotericin B Gilead liposomal will depend on your body weight. Fungal infections of one or more deep organs of the body: Treatment is normally started at 3 mg per kg of body weight, every day for a minimum of 14 days. The duration of therapy will be determined on an individual basis by your Doctor. Your doctor may decide to increase the amount you receive to as high as 5 mg per kg body weight. For mucormycosis the starting dose is normally 5 to 10 mg per kg of body weight per day. The duration of therapy will be determined on an individual basis by your Doctor. For HIV associated Cryptococcal meningitis a single dose of 10 mg/kg Amphotericin B Gilead liposomal, in combination with daily flucytosine 100 mg/kg and daily fluconazole 1200 mg, both administered for 14 days. Suspected fungal infections in patients with a raised temperature and neutropenia: The recommended daily dose is 3 mg per kg of body weight, per day. Your doctor may decide to increase the amount you receive to as high as 5 mg per kg body weight. Amphotericin B Gilead liposomal will be given to you until your temperature is normal for 3 days in a row. However, Amphotericin B Gilead liposomal must not be given for more than 42 days in a row. Visceral leishmaniasis: You may be given a total dose of between 21 and 30 mg per kg of body weight, over a period of 10 to 21 days. Your doctor will decide on the amount of Amphotericin B Gilead liposomal you will receive and over how many days it will be given.

Use in children and adolescents Amphotericin B Gilead liposomal has been used to treat children. The dose of Amphotericin B Gilead liposomal for a child is calculated per kg of body weight in the same way as for adults. Amphotericin B Gilead liposomal is not recommended in babies under 1 month old. Use in elderly patients No change in dose or frequency of infusion is needed for elderly patients. Use in patients with kidney problems Amphotericin B Gilead liposomal has been given to patients with kidney problems at doses ranging from 1 to 5 mg per kg of body weight per day. No change in dose or frequency of infusion is required. Your doctor or nurse will take regular blood samples to test for changes in kidney function during Amphotericin B Gilead liposomal treatment. How long will the infusion take? Normally the infusion will take 30 to 60 minutes. For doses greater than 5 mg per kg of body weight per day, the infusion could take up to 2 hours. If you receive a higher dose of Amphotericin B Gilead liposomal than you should You should tell your doctor immediately if you think you received too much Amphotericin B Gilead liposomal. If you have any further questions on the use of this product, ask your doctor.

4. Possible side effects Like all medicines, Amphotericin B Gilead liposomal can cause side effects, although not everybody gets them.

Possible side effects

during the infusion You may get side effects during the infusion: ▪

Very common (These can affect more than 1 in every 10 people): fever, chills, and shivering.

▪

Less frequent infusion-related side effects include: chest tightness, chest pain, breathlessness, difficulty breathing (possibly with wheezing), flushing, a faster heart rate than normal, low blood pressure and musculoskeletal pain (described as joint pain, back pain, or bone pain).

These side effects clear up quickly when the infusion is stopped. These reactions may not happen with future infusions of Amphotericin B Gilead liposomal or with a slower infusion (over 2 hours). Your doctor may give you other medicines to prevent infusion-related reactions, or to treat the symptoms if you do get them. If you have a severe infusion-related reaction, your doctor will stop the Amphotericin B Gilead liposomal infusion and you should not receive this treatment in the future. Very common side effects These can affect more than 1 in every 10 people:

  • Low blood potassium levels, leading to feeling tired, confused, having muscle weakness or cramps

▪ ▪

Feeling sick or being sick Fever, chills or shivering.

Common side effects These can affect up to 1 in every 10 people:

  • Low magnesium, calcium or sodium blood levels, leading to feeling tired, confused, muscle weakness or cramps
  • High blood sugar levels
  • Headache
  • A faster heart rate than normal
  • Widening of the blood vessels, causing low blood pressure and flushing
  • Breathlessness
  • Diarrhoea
  • Stomach (abdominal) pain
  • Rash
  • Chest pain
  • Back pain
  • Abnormal results for liver or kidney function showing up in blood tests or urine tests
  • High blood potassium levels. Uncommon side effects These can affect up to 1 in every 100 people:
  • Bleeding into the skin, unusual bruising and bleeding for a long time after injury
  • Severe allergic (anaphylactoid) reaction
  • Fits or seizures (convulsions)
  • Difficulty breathing, possibly with wheezing. Other side effects It is not known how frequently these side effects occur:
  • Anaemia (low red blood cell levels), with symptoms of excessive tiredness, being out of breath after light activity, and a pale complexion
  • Severe allergic (anaphylactic) or sensitivity reactions
  • Heart attacks and heart rhythm changes
  • Kidney failure and kidney problems. Signs include tiredness and passing less urine
  • Severe swelling of the skin around the lips, eyes or tongue.
  • Breakdown of muscle
  • Bone pain and joint pain Interference with Phosphorus blood test results. False readings showing an increase in the levels of phosphate in your blood may occur when samples from patients receiving Amphotericin B Gilead liposomal are analyzed using a specific system called a PHOSm assay. If your test results show high levels of phosphate, then further analysis using a different system may be necessary to confirm the results. Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system: United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard

How to store it

Amphotericin B Gilead liposomal Amphotericin B Gilead liposomal is stored in the hospital pharmacy. Keep this medicine out of the sight and reach of children. Do not use Amphotericin B Gilead liposomal after the date which is stated on the label after {EXP}. The expiry date refers to the last day of the month. Do not store above 25°C. Do not store partially used vials for future patient use. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

Contents of the pack and other information

What Amphotericin B Gilead liposomal contains The active ingredient is amphotericin B. Each vial contains 50 mg of amphotericin B enclosed inside liposomes (small fat particles). The other ingredients are: hydrogenated soy phosphatidylcholine, cholesterol, distearoylphosphatidylglycerol (sodium salt), alpha tocopherol, sucrose (sugar), disodium succinate hexahydrate, sodium hydroxide and hydrochloric acid. What Amphotericin B Gilead liposomal looks like and contents of the pack Amphotericin B Gilead liposomal is a sterile, bright yellow lyophilisate (freeze-dried powder) for dispersion for infusion.

It is presented in a 15-ml, 20-ml or 30-ml glass vial. Each vial contains 50 mg of the active ingredient amphotericin B. The closure consists of a rubber stopper and an aluminium ring seal fitted with a removable plastic cap.

Each carton contains 10 vials and 10 filters. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Gilead Sciences International Ltd Granta Park Abington Cambridge CB21 6GT United Kingdom Manufacturer

Gilead Sciences Ireland UC, IDA Business & Technology Park, Carrigtohill, County Cork, Ireland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: United Kingdom Gilead Sciences Ltd Tel: + 44 (0) 8000 113700 This leaflet was last revised in December 2024

<—————————————————————————————————-> The following information is intended for healthcare professionals only: READ THIS ENTIRE SECTION AND SECTION 4.4 CAREFULLY BEFORE BEGINNING RECONSTITUTION Amphotericin B Gilead liposomal is NOT equivalent to other amphotericin products. Amphotericin B Gilead liposomal must be reconstituted using Sterile Water for Injection (without a bacteriostatic agent) and diluted in Dextrose solution (5%, 10% or 20%) for infusion only. The use of any solution other than those recommended, or the presence of a bacteriostatic agent (e.g. benzyl alcohol) in the solution, may cause precipitation of Amphotericin B Gilead liposomal. Amphotericin B Gilead liposomal is NOT compatible with saline and must not be reconstituted or diluted with saline or administered through an intravenous line that has previously been used for saline unless first flushed with dextrose solution (5%, 10% or 20%) for infusion. If this is not feasible, Amphotericin B Gilead liposomal should be administered through a separate line. Do NOT mix Amphotericin B Gilead liposomal with other medicinal products or electrolytes. Aseptic technique must be strictly observed in all handling, since no preservative or bacteriostatic agent is present in Amphotericin B Gilead liposomal, or in the materials specified for reconstitution and dilution. Amphotericin B Gilead liposomal must be reconstituted by suitably trained staff. Vials of Amphotericin B Gilead liposomal containing 50 mg of amphotericin B are prepared as follows: If you need to reconstitute more than one vial, complete the whole reconstitution and dispersion process for one vial before adding the sterile water to the next vial. 1. Add 12 ml of Sterile Water for Injection to the Amphotericin B Gilead liposomal vial, to yield a preparation containing 4 mg/ml amphotericin B.

2. IMMEDIATELY after the addition of water, SHAKE THE VIAL VIGOROUSLY for 30 seconds to completely disperse the Amphotericin B Gilead liposomal. After reconstitution the concentrate is a translucent, yellow dispersion. Visually inspect the vial for particulate matter and continue shaking until complete dispersion is obtained. Do not use if there is any evidence of precipitation of foreign matter.

3. Calculate the amount of reconstituted Amphotericin B Gilead liposomal (4 mg/ml) to be further diluted (see table below). 4. The infusion solution is obtained by dilution of the reconstituted Amphotericin B Gilead liposomal with between one (1) and nineteen (19) parts dextrose solution (5%, 10% or 20%) for infusion by volume, to give a final concentration in the recommended range of 2.00 mg/ml to 0.20 mg/ml amphotericin B as Amphotericin B Gilead liposomal (see table below). 5. Withdraw the calculated volume of reconstituted Amphotericin B Gilead liposomal into a sterile syringe. Using the 5 micron filter provided, instill the Amphotericin B Gilead liposomal preparation into a sterile container with the correct amount of dextrose solution (5%, 10% or 20%) for infusion.

An in-line membrane filter may be used for intravenous infusion of Amphotericin B Gilead liposomal. However, the mean pore diameter of the filter should not be less than 1.0 micron. Example of the preparation of Amphotericin B Gilead liposomal dispersion for infusion at a dose of 3mg/kg/day in dextrose 5% solution for infusion. Weight (kg)

Number of vials

Amount Amphoterici n B Gilead liposomal (mg) to be withdrawn for further dilution

Volume of reconstituted Amphotericin B Gilead liposomal (ml)*

To make up a 0.2mg/ml concentration

To make up a 2.0mg/ml concentration

(1 in 20 dilution) (1 in 2 dilution) Volume of Total Volume of Total 5% volume (ml; 5% volume (ml; dextrose Amphoterici dextrose Amphoterici needed n B Gilead needed n B Gilead (ml) liposomal (ml) liposomal plus 5% plus 5% dextrose) dextrose) 10 1 30 7.5 142.5 150 7.5 15 25 2 75 18.75 356.25 375 18.75 37.5 40 3 120 30 570 600 30 60 55 4 165 41.25 783.75 825 41.25 82.5 70 5 210 52.5 997.5 1050 52.5 105 85 6 255 63.75 1211.25 1275 63.75 127.5 * Each vial of Amphotericin B Gilead liposomal (50mg) is reconstituted with 12ml Water for Injection to provide a concentration of 4mg/ml amphotericin B.

Any unused product or waste material should be disposed of in accordance with local requirements.

Frequently asked questions about Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome)

How do I take Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome)?

Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome) comes as infusion containing 50mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome)?

The active substance in Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome) is amphotericin b.

Are there equivalent medicines to Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome)?

Medicines with the same active substance, strength and form include: Amphotericin B Tillomed liposomal 50 mg powder for dispersion for infusion. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome) without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Amphotericin b (3 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Amphotericin B Gilead liposomal is indicated in adults and children aged 1 month to 18 years old for:

• the treatment of severe systemic and/or deep mycoses

• the treatment of visceral leishmaniasis in immunocompetent patients including both adults and children

• the empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause.

Infections successfully treated with Amphotericin B Gilead liposomal include: disseminated candidiasis, aspergillosis, mucormycosis, chronic mycetoma, cryptococcal meningitis and visceral leishmaniasis.

Amphotericin B Gilead liposomal should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.

4.2. Posology and method of administration

Non-equivalence of amphotericin products

Different amphotericin products (sodium deoxycholate, liposomal, lipid complex) are not equivalent in terms of pharmacodynamics, pharmacokinetics and dosing and so the products should not be used interchangeably without accounting for these differences. Both the trade name, common name and dose should be verified pre-administration.

There is a risk of under-dose if Amphotericin B Gilead liposomal is administered at a dose recommended for amphotericin B deoxycholate.

Posology

Anaphylaxis and anaphylactoid reactions can occur at any point of treatment of Amphotericin B Gilead liposomal therefore the patient should be monitored closely during every treatment of Amphotericin B Gilead liposomal (see section 4.4).

Treatment of mycoses

Therapy is usually instituted at a daily dose of 3 to 5 mg/kg of body weight for a minimum of 14 days. Dosage of amphotericin B as Amphotericin B Gilead liposomal must be adjusted to the specific requirements of each patient.

Mucormycosis

For suspected or confirmed infection, the recommended starting dose is 5 to 10 mg/kg/day. In patients with brain involvement or solid-organ transplant, dose at 10 mg/kg/day. Avoid slow escalation of doses. The duration of therapy should be determined on an individual basis. Courses of up to 6 – 8 weeks are commonly used in clinical practice; longer durations of therapy may be required for deep seated infections or in cases of prolonged courses of chemotherapy or neutropenia.

Although doses greater than 5 mg/kg and up to a maximum of 10 mg/kg have been used in clinical trials and clinical practice, data on the safety and efficacy of Amphotericin B Gilead liposomal for the treatment of mucormycosis at these higher doses are limited. Therefore, a benefit:risk assessment should be made on an individual patient level to determine whether the potential benefits of treatment are considered to outweigh the known increased risk of toxicity at higher Amphotericin B Gilead liposomal doses (see section 4.4 ).

HIV associated Cryptococcal meningitis

Administer a single dose of 10 mg/kg Amphotericin B Gilead liposomal on day 1, in combination with daily flucytosine 100 mg/kg and daily fluconazole 1200 mg, both administered for 14 days.

After the 2-week induction period, patients should receive fluconazole 800 mg daily for 8 weeks and then at a dose of 200 mg daily thereafter at the treating physician's discretion.

Treatment of visceral leishmaniasis

A total dose of 21.0 - 30.0 mg/kg of body weight given over 10-21 days may be used in the treatment of visceral leishmaniasis. Particulars as to the optimal dosage and the eventual development of resistance are as yet incomplete. The product should be administered under strict medical supervision.

Empirical treatment of febrile neutropenia

The recommended daily dose is 3 to 5 mg/kg body weight per day. Treatment should be continued until the recorded temperature is normalised for 3 consecutive days. In any event, treatment should be discontinued after a maximum of 42 days.

Paediatric population

Both systemic fungal infections in children and presumed fungal infections in children with febrile neutropenia have been successfully treated with Amphotericin B Gilead liposomal, without reports of unusual adverse events. Amphotericin B Gilead liposomal has been studied in paediatric patients aged one month to 18 years old. Doses used in these clinical studies were the same as those used in adults on a mg/kg body weight basis.

Amphotericin B Gilead liposomal is not recommended for use in children below 1 month old due to lack of data on safety and efficacy.

Elderly patients

No alteration in dose or frequency of dosing is required.

Renal impairment

Amphotericin B Gilead liposomal has been administered to a large number of patients with pre-existing renal impairment at starting doses ranging from 1-3 mg/kg/day in clinical trials and no adjustment in dose or frequency of administration was required (See section 4.4).

Hepatic impairment

No data are available on which to make a dose recommendation for patients with hepatic impairment (See section 4.4).

Method of administration

Amphotericin B Gilead liposomal should be administered by intravenous infusion over a 30 - 60 minute period and the patient closely observed. For doses greater than 5mg/kg/day, intravenous infusion over a 2 hour period is recommended (see section 4.4). The recommended concentration for intravenous infusion is 0.20 mg/ml to 2.00 mg/ml amphotericin B as Amphotericin B Gilead liposomal.

For instructions on reconstitution and dilution of the product before administration, see section 6.6.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 unless, in the opinion of the physician, the condition requiring treatment is life-threatening and amenable only to Amphotericin B Gilead liposomal therapy.

4.4. Special warnings and precautions for use

Anaphylaxis and anaphylactoid reactions

Anaphylaxis and anaphylactoid reactions have been reported in association with Amphotericin B Gilead liposomal infusion. Allergic type reactions, including severe infusion-related reactions can occur during administration of amphotericin-containing products, including Amphotericin B Gilead liposomal (see section 4.8). Therefore, every dose of Amphotericin B Gilead liposomal should be infused over 30-60 minutes and the patient closely monitored every time. If a severe allergic or anaphylactic/anaphylactoid reaction occurs, the infusion should be immediately discontinued and the patient should not receive further infusion of Amphotericin B Gilead liposomal.

Infusion-related reactions

Other severe infusion-related reactions can occur during administration of amphotericin B-containing products, including Amphotericin B Gilead liposomal (see section 4.8). Although infusion-related reactions are not usually serious, consideration of precautionary measures for the prevention or treatment of these reactions should be given to patients who receive Amphotericin B Gilead liposomal therapy. Slower infusion rates (over 2 hours) or routine doses of diphenhydramine, paracetamol, pethidine and/or hydrocortisone have been reported as successful in their prevention or treatment.

Renal toxicity

Amphotericin B Gilead liposomal has been shown to be substantially less toxic than conventional amphotericin B, particularly with respect to nephrotoxicity; however, renal adverse reactions may still occur.

In studies comparing Amphotericin B Gilead liposomal 3 mg/kg daily with higher doses (5, 6 or 10 mg/kg daily), it was found that the incidence rates of increased serum creatinine, hypokalaemia and hypomagnesaemia were notably higher in the high dose groups.

In particular, caution should be exercised when prolonged therapy is required. Regular laboratory evaluation of serum electrolytes, particularly potassium and magnesium as well as renal, hepatic and haematopoietic function should be performed, at least once weekly. Renal function should be closely monitored in these patients. Due to the risk of hypokalaemia, appropriate potassium supplementation may be required during the course of Amphotericin B Gilead liposomal administration. If clinically significant reduction in renal function or worsening of other parameters occurs, consideration should be given to dose reduction, treatment interruption or discontinuation. Cases of hyperkalaemia (some of them leading to cardiac arrhythmias and cardiac arrest) have been reported. Most of them occurred in patients with renal impairment, and some cases after potassium supplementation in patients with previous hypokalaemia. Therefore, renal function and laboratory evaluation of potassium, should be measured before and during treatment. This is particularly important in patients with pre-existing renal disease, who have already experienced renal failure, or in patients receiving concomitant nephrotoxic medications (see section 4.5).

Pulmonary toxicity

Acute pulmonary toxicity has been reported in patients given amphotericin B (as sodium deoxycholate complex) during or shortly after leukocyte transfusions. It is recommended that these infusions are separated by as long a period as possible and pulmonary function should be monitored.

Diabetic patients

Amphotericin B Gilead liposomal contains approximately 900 mg of sucrose in each vial. This should be taken into account when treating diabetic patients.

This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

No specific interaction studies have been performed with Amphotericin B Gilead liposomal. However, the following medicinal products are known to interact with amphotericin B and may interact with Amphotericin B Gilead liposomal:

Nephrotoxic medications

Concurrent administration of Amphotericin B Gilead liposomal with other nephrotoxic agents (for example ciclosporin, aminoglycosides, polymixins, tacrolimus and pentamidine) may enhance the potential for drug-induced renal toxicity in some patients. However, in patients receiving concomitant ciclosporin and/or aminoglycosides, Amphotericin B Gilead liposomal was associated with significantly less nephrotoxicity compared to amphotericin B. Regular monitoring of renal function is recommended in patients receiving Amphotericin B Gilead liposomal with any nephrotoxic medications.

Corticosteroids, corticotropin (ACTH) and diuretics

Concurrent use of corticosteroids, ACTH and diuretics (loop and thiazide) may potentiate hypokalemia.

Digitalis glycosides

Amphotericin B Gilead liposomal-induced hypokalemia may potentiate digitalis toxicity.

Skeletal muscle relaxants

Amphotericin B Gilead liposomal-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g. tubocurarine).

Antifungals

Whilst synergy between amphotericin and flucytosine has been reported, concurrent use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion, therefore a benefit:risk assessment should be made on an individual patient level.

Antineoplastic agents

Concurrent use of antineoplastic agents may enhance the potential for renal toxicity, bronchospasm and hypotension. Antineoplastic agents should be given concomitantly with caution.

Leukocyte transfusions

Acute pulmonary toxicity has been reported in patients given amphotericin B (as sodium deoxycholate complex) during or shortly after leukocyte transfusions. It is recommended these infusions are separated by as long a period as possible and pulmonary function should be monitored.

4.6. Fertility, pregnancy and lactation

Pregnancy

The safety of Amphotericin B Gilead liposomal in pregnant women has not been established.

Systemic fungal infections have been successfully treated in pregnant women with conventional amphotericin B without obvious effect on the fetus, but the number of cases reported is insufficient to draw any conclusions on the safety of Amphotericin B Gilead liposomal in pregnancy.

Amphotericin B Gilead liposomal should only be used during pregnancy if the possible benefits to be derived outweigh the potential risks to the mother and fetus.

Breast-feeding

It is unknown whether Amphotericin B Gilead liposomal is excreted in human breast milk. A decision on whether to breastfeed while receiving Amphotericin B Gilead liposomal should take into account the potential risk to the child as well as the benefit of breast feeding for the child and the benefit of Amphotericin B Gilead liposomal therapy for the mother.

Fertility

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. Some of the undesirable effects of Amphotericin B Gilead liposomal presented below may impact the ability to drive and use machines.

4.8. Undesirable effects

Summary of adverse reactions

The following adverse reactions have been attributed to Amphotericin B Gilead liposomal based on clinical trial data and post-marketing experience. The frequency is based on analysis from pooled clinical trials of 688 Amphotericin B Gilead liposomal treated patients; the frequency of adverse reactions identified from post-marketing experience is not known. Adverse reactions are listed below by body system organ class using MedDRA and are sorted by frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Frequencies are defined as:

Very common

(≥ 1/10)

Common

(≥ 1/100 to < 1/10)

Uncommon

(≥ 1/1,000 to < 1/100)

Very rare

(<1/10,000),

Not known

(cannot be estimated from the available data)

Blood and lymphatic system disorders

Uncommon: thrombocytopenia

Not known: anaemia

Immune system disorders

Uncommon: anaphylactoid reaction

Not known: anaphylactic reactions, hypersensitivity

Metabolism and nutrition disorders

Very common: hypokalaemia

Common: hyponatraemia, hypocalcaemia, hypomagnesaemia, hyperglycaemia, hyperkalaemia

Nervous system disorders

Common: headache

Uncommon: convulsion

Cardiac disorders

Common: tachycardia

Not known: cardiac arrest, arrhythmia

Vascular disorders

Common: hypotension, vasodilatation, flushing

Respiratory, thoracic and mediastinal disorders

Common: dyspnoea

Uncommon: bronchospasm

Gastrointestinal disorders

Very common: nausea, vomiting

Common: diarrhoea, abdominal pain

Hepatobiliary disorders

Common: abnormal liver function tests, hyperbilirubinaemia, increased alkaline phosphatase

Skin and subcutaneous disorders

Common: rash

Not known: angioneurotic oedema

Musculoskeletal and connective tissue disorders

Common: back pain

Not Known: rhabdomyolysis (associated with hypokalaemia), musculoskeletal pain (described as arthralgia or bone pain)

Renal and urinary disorders

Common: increased creatinine, increased blood urea

Not known: renal failure, renal insufficiency

General disorders and administration site conditions

Very Common: rigors, pyrexia,

Common: chest pain

Description of selected adverse reactions

Infusion-related reactions

Fever and chills/rigors are the most frequent infusion-related reactions expected to occur during Amphotericin B Gilead liposomal administration. Less frequent infusion-related reactions may consist of one or more of the following symptoms: chest tightness or pain, dyspnoea, bronchospasm, flushing, tachycardia, hypotension and musculoskeletal pain (described as arthralgia, back pain, or bone pain). These resolve rapidly on stopping the infusion and may not occur with every subsequent dose or when slower infusion rates (over 2 hours) are used. In addition, infusion-related reactions may also be prevented by the use of premedication. However, severe infusion-related reactions may necessitate the permanent discontinuation of Amphotericin B Gilead liposomal (see section 4.4).

In two double-blind, comparative studies, Amphotericin B Gilead liposomal treated patients experienced a significantly lower incidence of infusion-related reactions, as compared to patients treated with conventional amphotericin B or amphotericin B lipid complex.

In pooled study data from randomised, controlled clinical trials comparing Amphotericin B Gilead liposomal with conventional amphotericin B therapy in greater than 1,000 patients, reported adverse reactions were considerably less severe and less frequent in Amphotericin B Gilead liposomal treated patients as compared with conventional amphotericin B treated patients.

A randomized phase III study assessed a single 10 mg/kg dose of Amphotericin B Gilead liposomal with a backbone of 14 days flucytosine and fluconazole, compared to the control group (1-week conventional amphotericin B plus flucytosine followed by 1 week of fluconazole) in the treatment of HIV associated cryptococcal meningitis. The Amphotericin B Gilead liposomal treated patients experienced fewer grade 3 or 4 adverse events compared to the control group. The safety profile observed in this patient population was consistent with the overall safety profile for Amphotericin B Gilead liposomal.

Renal toxicity

Nephrotoxicity occurs to some degree with conventional amphotericin B in most patients receiving the product intravenously. In a double-blind study involving 687 patients, the incidence of nephrotoxicity with Amphotericin B Gilead liposomal (as measured by serum creatinine increase greater than 2.0 times baseline measurement), was approximately half that for conventional amphotericin B. In another double-blind study involving 244 patients, the incidence of nephrotoxicity with Amphotericin B Gilead liposomal (as measured by serum creatinine increase greater than 2.0 times baseline measurement) was approximately half that for Amphotericin B lipid complex.

Interference with Phosphorus Chemistry Assay

False elevations of serum phosphate may occur when samples from patients receiving Amphotericin B Gilead liposomal are analyzed using the PHOSm assay (e.g. used in Beckman Coulter analyzers including the Synchron LX20). This assay is intended for the quantitative determination of inorganic phosphorus in human serum, plasma or urine samples.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:

United Kingdom

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard

4.9. Overdose

The toxicity of Amphotericin B Gilead liposomal due to acute overdose has not been defined. If overdose should occur, cease administration immediately. Carefully monitor clinical status including renal and hepatic function, serum electrolytes and haematological status. Haemodialysis or peritoneal dialysis does not appear to affect the elimination of Amphotericin B Gilead liposomal.

Special populations (including paediatric population):

No additional information is available in special populations.

💬 Ask about this leaflet

Ask anything about Amphotericin B Gilead liposomal 50 mg Powder for dispersion for infusion (previously known as AmBisome). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →